Background: The present study was designed to verify the efficacy of cognitive-behavioral group therapy (CBGT) in reducing obsessive-compulsive symptoms and the intensity of overvalued ideas, as well as in improving the patient’s quality of life. Methods: Forty-seven patients meeting DSM-IV criteria for obsessive-compulsive disorder (OCD) were randomly assigned to either 12 weekly CBGT sessions or a waiting list (control group). Treated patients were followed for three months. Results: There was a significant reduction in the Yale-Brown Obsessive-Compulsive Scale (p < 0.001), in the National Institute of Mental Health Obsessive-Compulsive Scale (p < 0.001), in the Overvalued Ideas Scale (p < 0.001), and a significant improvement in the quality of life in the four domains of the World Health Organization Quality of Life Assessment Scale: physical (p < 0.001), psychological (p < 0.017), social (p < 0.018) and environmental (p < 0.04). No significant reduction was found in the Hamilton Rating Scale for Anxiety (p = 0.111) and the Hamilton Rating Scale for Depression (p = 0.271). The concomitant use of anti-obsessional medications did not influence the results. The rate of improved patients was 69.6% in the treated group and 4.2% in the control group (p < 0.001). The therapeutic gains were maintained and an additional reduction in symptoms was observed during the 3-month follow-up period. Conclusions: The results suggest that CBGT is effective in reducing the intensity of OCD symptoms and of overvalued ideas, and that it improves the OCD patient’s quality of life in a short period of time.

Keywords:
Obsessive-compulsive disorder, Cognitive-behavioral group therapy, Group therapy, Behavior therapy, Cognitive therapy, Quality of life
1.
March JS, Frances A, Carpenter D, et al: The Expert Consensus Guideline Series – Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 4):13–72.
2.
Salkovskis PM: Obsessional-compulsive problems: A cognitive-behavioral analysis. Behav Res Ther 1985;23:571–583.
3.
Van Oppen P, Arntz A: Cognitive therapy for obsessive-compulsive disorder. Behav Res Ther 1994;32:79–87.
4.
Freeston MH, Rhéaume J, Ladoucer R: Correcting faulty appraisals of obsessional thoughts. Behav Res Ther 1996;34:433–446.
5.
Freeston MH, Ladouceur R, Gagnon F, Thibodeau N, Rhéaume J, Letarte H, Bujold A: Cognitive-behavioral therapy treatment of obsessive-compulsive thoughts: A controlled study. J Consult Clin Psychol 1997;65:405–413.
6.
Krone KP, Himle JA, Nesse RM: A standardized behavioral group treatment program for obsessive-compulsive disorder: Preliminary outcomes. Behav Res Ther 1991;29:627–631.
7.
Falls-Stewart W, Marks AP, Schafer BA: A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. J Nerv Ment Dis 1993;181:189–193.
8.
Van Noppen B, Steketee G, McCorkle MA, Pato M: Group and multifamily behavioral treatment for obsessive-compulsive disorder: a pilot study. J Anxiety Disord 1997;11:431–446.
9.
McLean PD, Whittal ML, Söchting I, Koch WJ, Paterson R, Thordarson DS, Taylor SM, Anderson K: Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J Consult Clin Psychol 2001;69:205–214.
10.
Lecrubier Y, Weiller E, Hergueta T, Amorim P, Bonora LI, Lépine JP, Sheehan D, Janavs J, Baker R, Sheehan KH, Knapp E, Sheehan M: The Mini International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview (MINI) for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22–33.
11.
Amorim P: Mini International Neuropsychiatric Interview (MINI): Validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr 2000;22:106–115.
12.
Goodman WK, Price LH, Rasmussen AS, Mazure R, Fleishman R, Hill C, Heninger G, Charney D: The Yale-Brown Obsessive-Compulsive Scale: Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006–1016.
13.
Jenike MA, Baer L, Minichiello WE: Obsessive-Compulsive Disorders: Theory and Management, ed 2. Chicago, Year Book, 1990, p 408.
14.
Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–55.
15.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–61.
16.
Neziroglu FA, Stevens KP, Yaryura-Tobias JA: Overvalued ideas and their impact on treatment outcome. Rev Bras Psiquiatr 1999;21:209–216.
17.
Marks IM, Hodgson R, Rachman S: Treatment of chronic obsessive-compulsive neurosis by in vivo exposure: A two-year follow-up and issues in treatment. Br J Psychiatry 1975;127:349–364.
18.
Baer L: Getting Control – Overcoming Your Obsessions and Compulsions. New York, Plume, 2000.
19.
Salkovskis PM: Understanding and treating obsessive-compulsive disorder. Behav Res Ther 1999;37:29–52.
20.
Kobak KA, Rock AL, Greist JH: Group behavior therapy for obsessive-compulsive disorder. J Spec Group Work 1995;20:26–32.
21.
Van Noppen B, Pato M, Marsland R, Rasmussen SA: A time-limited behavioral group for treatment of obsessive-compulsive disorder. J Psychother Pract Res 1998;7:272–280.
22.
Vinogradov S, Yalom I: A concise guide to group psychotherapy. Washington, American Psychiatric Press, 1989.
23.
Cordioli AV, Heldt E, Bochi DB, Margis M, de Sousa MB, Tonello JF, Teruchkin B, Kapczinski F: Time-limited cognitive-behavioral group therapy in the treatment of obsessive-compulsive disorder: An open clinical trial. Rev Bras Psiquiatr 2002;24:113–120.
24.
Obsessive Compulsive Cognitions Working Group: Cognitive assessment of obsessive-compulsive disorder. Behav Res Ther 1997;9:667–681.
25.
Beck AT: Cognitive Therapy and the Emotional Disorders. New York, International University Press, 1976.
26.
Van Oppen P, De Haan E, Van Balkon AJLM, Spinhoven P, Hoogduin K, Van Dyck R: Cognitive therapy and exposure in vivo in the treatment of obsessive-compulsive disorder. Behav Res Ther 1995;4:379–390.
27.
Clomipramine Collaborative Study Group: Clomipramine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730–738.
28.
Kobak KA, Greist JH, Jefferson JW, Katzlenik DJ, Henk HJ: Behavior versus pharmacological treatments of obsessive-compulsive disorder. Psychopharmacology 1998;136:205–216.
29.
Simpson BH, Gorfinkle KS, Liebowitz MR: Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: An open trial. J Clin Psychiatry 1999;60:584–590.
30.
Cottraux J, Note I, Yao SN, Lafont S, Note B, Mollard E, Bouvard M, Sauteraud A, Bourgeois M, Dartigues JF: A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive-compulsive disorder. Psychother Psychosom 2001;70:288–297.
31.
Greist JH, Marks IM, Baer L, Kobak KA, Wenzel KW, Hirsch J, Mantle JM, Clary C: Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry 2002;63:138–145.
32.
Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L: Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behavior therapy: Results from a controlled trial. Psychother Psychosom 2002;71:255–262.
33.
Marks IM, O’Sullivan G: Drugs and psychological treatments for agoraphobia/panic and obsessive-compulsive disorders: a review. Br J Psychiatry 1988;153:650–655.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.